Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

Research & Development

Evidence

Clinical Trials

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Read More →

Products

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Immunix®

Sepsis ImmunoScore®

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Read More →

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Resource Library

Events

Treating the Patient, Not the Disease

Read More →

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore Outperforms Conventional Sepsis Tools

Read More →

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Awards

LifeBridge Health deploys Prenosis’ FDA-authorized AI tool to speed sepsis detection

Read More →

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Originally published June 24, 2026 in MDPI Diagnostics  |  Read the full article

ABSTRACT | The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Background: Early and accurate risk stratification of patients suspected of serious infection is essential for improving outcomes, but existing diagnostic and predictive tools have limited accuracy. The objective was to compare the performance of an FDA-authorized AI diagnostic test, the Sepsis ImmunoScore, against widely available biomarkers and clinical tools for diagnosis of sepsis and prediction of in-hospital mortality and intensive care unit (ICU) admission.

Methods: This multicenter observational study included 6027 adult patients suspected of infection across 7 U.S. hospital sites. The Sepsis ImmunoScore’s predictive performance was compared to the sequential organ failure assessment (SOFA) score, procalcitonin (PCT), C-reactive protein (CRP), Systemic Inflammatory Response Syndrome (SIRS) score, National Early Warning Score (NEWS), and quick SOFA (qSOFA). Primary outcomes included sepsis as defined by Sepsis-3 criteria, in-hospital mortality, and ICU admission. Predictive accuracy was assessed using area under the receiver operating characteristic curve (AUC), and 95% confidence intervals were generated and hypothesis testing conducted using the bootstrap method.

Results: The Sepsis ImmunoScore demonstrated statistically significant superior performance across all outcomes. For sepsis prediction, the Sepsis ImmunoScore achieved an AUC of 0.82, compared to SOFA (0.72), procalcitonin (PCT) (0.70), C-reactive protein (CRP) (0.61), SIRS (0.59), NEWS (0.69), and qSOFA (0.67). For in-hospital mortality prediction, the Sepsis ImmunoScore achieved an AUC of 0.80, outperforming SOFA (0.72), PCT (0.67), CRP (0.58), SIRS (0.60), NEWS (0.72), and qSOFA (0.69). For ICU admission, the Sepsis ImmunoScore reached an AUC of 0.74, superior to SOFA (0.63), PCT (0.64), CRP (0.54), SIRS (0.60), NEWS (0.70), and qSOFA (0.65). All differences between the Sepsis ImmunoScore and comparators were statistically significant.

Conclusions: The Sepsis ImmunoScore significantly improved predictive accuracy for sepsis, in-hospital mortality, and ICU admission compared to six conventional clinical scores and biomarkers. This AI-based tool may enhance risk stratification and clinical decision-making, potentially leading to more timely sepsis interventions and improved outcomes.

Read the full article in MDPI Diagnostics.